Dermapharm Holding SE (CHIX:DMPD) Total Current Liabilities: €390 Mil (As of Mar. 2026)


CHIX:DMPD Dermapharm Holding SE CHIX:DMPD
80 GF Score
Price €46.18
GF Value €38.59
! 9 Warning Signs
View Full Analysis

What is Dermapharm Holding SE Total Current Liabilities?

Dermapharm Holding SE CHIX:DMPD 80 Total Current Liabilities is €390 Mil as of Mar. 2026. GuruFocus rates CHIX:DMPD with a GF Score™ of 80/100 and a GF Value™ of €38.59. The stock has 9 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Dermapharm Holding SE's total current liabilities for the quarter that ended in Mar. 2026 was €390

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Dermapharm Holding SE Total Current Liabilities Related Terms

Dermapharm Holding SE Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Dermapharm Holding SE's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE Total Current Liabilities Chart

Dermapharm Holding SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 155.61 217.79 394.49 326.92 342.93

Dermapharm Holding SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 306.74 360.29 292.55 342.93 390.24
CHIX:DMPD
80GF Score
Dermapharm Holding SE CHIX:DMPD
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermapharm Holding SE Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Dermapharm Holding SE's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=133.208+129.383
+Other Current Liabilities+Current Deferred Liabilities
=80.339+0
=343

Dermapharm Holding SE's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=146.577+0
+Other Current Liabilities+Current Deferred Liabilities
=243.664+0
=390

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of €390 Mil mean?
Dermapharm Holding SE (CHIX:DMPD) has a Total Current Liabilities of €390 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Dermapharm Holding SE and its competitors.
Is Dermapharm Holding SE's Total Current Liabilities too high?
Dermapharm Holding SE's current Total Current Liabilities is €390 Mil. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's Total Current Liabilities compare to ZTS and UTHR?
Dermapharm Holding SE's Total Current Liabilities of €390 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Dermapharm Holding SE and its competitors. Dermapharm Holding SE's current Total Current Liabilities is €390 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current Total Current Liabilities of €390 Mil. The stock's GF Value™ is €38.59, compared to a current price of €46.18 — trading 19.7% above its estimated fair value. The current Total Current Liabilities is €390 Mil. Dermapharm Holding SE's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current Total Current Liabilities is €390 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?

Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued. The current stock price of €46.18 is trading 19.7% above its estimated GF Value™ of €38.59.

Key valuation signals for CHIX:DMPD:

  • Total Current Liabilities: €390 Mil
  • GF Value™: €38.59 vs. price of €46.18 (19.7% above fair value)
  • GF Score™: 80/100 with 9 warning signs

No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dermapharm Holding SE Business Description

Other Exchanges DMPHF:USA0A5J:UKDMP:Germany
Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score

Get the complete analysis for CHIX:DMPD

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.18
Price
€38.59
GF Value